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1. Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as TB bacilli revealing resistance to at
least isoniazid and rifampicin whereas extensively drug-resistant tuberculosis (XDR-TB) is TB
bacilli that develops resistance to at least isoniazid and rifampicin as well as to any quinolone
drug and at least one of the second-line anti-TB injectable drug : kanamycin, amikacin, or
capreomycin. Report from the World Health Organization (WHO)/International Union
Against Tuberculosis and Lung Disease (IUATLD) Global Project on Drug Resistance Surveil‐
lance revealed that the prevalence of the primary multidrug-resistant tuberculosis during
1996-1999 ranged between 0-14.1 % [1]. In 1994, the first WHO-IUATLD global anti-TB drug
resistance surveillance was carried out in 35 countries and subsequently, the second, third and
fourth surveillances occurred in 1996-1999, 1999-2002 and 2002-2007, respectively. The
emergence of clinically significant MDR-TB was in the early 1990s. Reports of Primary Drug-
Resistance Surveillance in Thailand during 1997-1998, 2001-2002, and 2005-2006 were 2.02 %
[2], 0.93 % [3], and 1.65 % [4], respectively while the secondary drug-resistance in 2005-2006
revealed 34.54 % [4]. However, number of patients with MDR-TB demonstrated in 2008 Annual
Report of the Bureau of Tuberculosis, Thailand were only 294 while the WHO’ s estimated
number of patients were 2,774 [5]. The prevalence of primary plus secondary MDR-TB among
prisoners in Thailand in 2002-2003 was 5.3 % while the prevalence of primary MDR-TB was
5.9 % [6]. Report from the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai,
Thailand, 10th office of Disease prevention and Control, Department of Disease Control,
Ministry of Public Health, Thailand in 2011 revealed only 88 patients who registered with
MDR-TB at hospitals in northern Thailand [7] while only 16.3 %, 18.6 % and 18.6 % of 43 patients
with laboratory confirmation were cure, completeness of treatment, and dead, respectively in
2009 report [8]. Findings from the Bureau of Tuberculosis of Thailand ‘ s 2007-2009 Research
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Project on Anti-tuberculosis Drug Resistance Surveillance in Thailand (Situation of Multidrug-
Resistant Tuberculosis in Thailand : Fiscal Year 2007-2009) that studied in 126 hospitals
countrywide showed 877 patients with laboratory-confirmed MDR-TB and 64 patients with
laboratory-confirmed XDR-TB while 21.5 % were dead and 12.74 % of these MDR/XDR-TB
patients had human immunodeficiency virus (HIV) infection /acquired immunodeficiency
syndrome (AIDS) compared to 21.57% of probable or presumptive MDR-TB patients co-
infected with HIV/AIDS [9]. Only 18.2% of the studied data sources came from TB registered
book for MDR-TB patients and most of them came from the hospital medical registry [9]. A
previous study by Scano F et al. revealed 52 of the 53 patients with XDR-TB died [10]. The
median survival time from collection of specimen to death of these patients was 16 days [10].
The prevalence of XDR-TB among all MDR-TB patient was as the following : 10.3% in Germany
and 14.3% in Italy (1993-2004) ; 1.5% in Asia, 15.4% in Republic of Korea, 13.6% in Russia, 0.6%
in Africa and Middle East, 6.5% in industrialized countries, and 6.6% overall worldwide
(2000-2004); 12% in Hong Kong (2004); 10.9% in Iran (2006); 7.3% in India; and 4% in France
(2006) [11]. The WHO notified that Thailand possibly underreported of MDR/XDR-TB
prevalence due to delaying of transportation of the specimens for anti-tuberculosis drug
susceptibility testing to the specialized centres and processes of unstandardized data collecting
of the country [9]. More than 400,000 new MDR-TB cases globally occur each year while
approximately half of a million cases occurred in 2007 and accounted for more than 5% of the
annually global cases of TB disease. The emerging of drug-resistant TB is a global health
problem, although emphasis has been placed on several “ hotspots ” (higher than 3% of its
prevalence) worldwide because of lacking of good global data reported to the WHO. The
emergence of MDR-TB and XDR-TB is a real health threat to achieve TB elimination.
2. Epidemiology
Development of anti-tuberculosis drug resistance can occur due to Mycobacterium tuberculo‐
sis genetic factor, previous anti-tuberculosis treatment-related factors and many other factors
[11]. The mechanism of drug-resistance is shown in Figure 1. There is a constant rate of
spontaneous mutation of 0.0033 mutations/deoxyribonucleic acid (DNA) replication that is
unique for a diverse spectrum of prokaryotic organisms [12]. The average rates of spontaneous
mutation for rifampicin, isoniazid, pyrazinamide, streptomycin, and ethambutol are 2.25 x
10-10, 2.56 x 10-8, 1 x 10-3, 2.95 x 10-8, and 1.0 x 10-7, respectively [13]. A previous study in India
revealed 3.4% and 25% of primary and acquired MDR-TB, respectively [14] which were higher
than the primary MDR-TB and acquired MDR-TB prevalence previously surveyed in Thailand
[2,3,4]. Liu CH et al. reported their study in China which presented 19.4% of MDR-TB, 1.3% of
XDR-TB, 19.8% of poly-resistant TB, and 47.1% of any anti-tuberculosis drug resistance [15].
A surveillance data in 2007 from the WHO demonstrated 4.8% of MDR-TB cases among new
TB cases worldwide [16] compared to the study from MDR-TB surveillance in Thailand
between 2007-2009 revealed the MDR-TB prevalence of 0-0.21% (average 0.08%) which was
highest in the central part of Thailand [9]. The prevalence among patients with previously TB
treatment from the same surveillance project was between 1.58-58.72% (average 8.49%, higher
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than the percentage of hotspot of MDR-TB prevalence set by the WHO (3%, an indicator for
implementation of DOTS (Directly Observed Treatment, Short Course)-Plus programmes)
which was also found highest in the central part of Thailand while the northern part of Thailand
was the second [9]. This Thailand’s serious MDR-TB situation needs urgently management
such as implementation of DOTS-Plus programmes. In 2006, Gandhi NR et al. firstly reported
of XDR-TB co-infected with HIV/AIDS which had been studied in Kwazulu Natal, South Africa
(KZN) [11]. XDR-TB epidemic in South Africa appears to be the primary mechanism through
the acquisition of 63-75% of XDR-TB cases [11] whereas the strain of Mycobacterium tuberculo‐
sis infected among a large number of XDR-TB cases in KZN was F15/LAM4/KZN [11].
Generally, individual who is infected with Mycobacterium tuberculosis has approximately 5-10%
lifetime risk of developing TB disease, but in an individual with HIV-infection/AIDS the risk
is 5-15% a year [11]. This can contribute HIV-infection/AIDS to facilitate the control of
outbreaks of MDR-TB and XDR-TB, although it has contributed to outbreaks of drug-resistant
TB [17]. The patients with MDR-TB and HIV/AIDS co-infection will have exceedingly high
mortality [16]. Gandhi NR et al. recently reported their study on risk factors for mortality
among MDR/XDR-TB patients with HIV/AIDS co-infection which revealed that 80% of XDR-
TB patients died whereas 63% of MDR-TB patients were dead following the diagnosis [18].
The CD4-T cell count less than 50 cells/mm3 was the strongest independent factor for mortality
among both patient groups [18]. History of TB treatment is the most significant predictor of
development of MDR-TB [19]. High prevalence of HIV/AIDS co-infection and inadequate
resources for case detection and management have contributed to the emergence of untreatable
XDR-TB [20]. Unfortunately, the presence of XDR-TB in non—HIV-infected patients with
MDR-TB is independent poor prognostic factors [11]. Prevalence of XDR-TB is globally
accounted for approximately 5.4% of MDR-TB prevalence [21]. Drug-resistant TB and drug-
resistant gram-negative bacterial infection and disease are associated with the most serious
health problems in developing countries [22]. Estimated 81,000 patients with MDR-TB (18.4%
of the estimated MDR-TB patients worldwide in 2011) live in the 53 countries of the WHO
European Region [23]. This European MDR-TB problem contributed to launching of a new
WHO Regional Office for Europe Action Plan to fight MDR-TB to contain the spread of drug-
resistant TB in the region by the end of 2015 [23]. The new action plan set the targets to be
achieved by the end of 2015, are : 1) decreasing 20% of the proportion of MDR-TB cases among
previously treated patients 2) diagnosis of at least 85% of the estimated MDR-TB cases and 3)
treating successfully at least 75% of notified MDR-TB cases [23]. If this plan is fully imple‐
mented and expected, by 2015, to successfully treat 127,000 MDR-TB cases, and to prevent the
emergence of 250,000 new MDR-TB cases and 13,000 new XDR-TB cases [23]. This would
interrupt the transmission of MDR-TB and save 120,000 lives in this region [23].
3. Systematic management of MDR/XDR-TB
Diagnostic and treatment consultation networks for MDR/XDR-TB which set by the 10th Zonal
Tuberculosis and Chest Disease Centre, Chiang Mai, 10th Office of Disease Prevention and
Control, Department of Disease Control, Ministry of Public Health, Thailand beyond the year
Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand
http://dx.doi.org/10.5772/54852
241
2000 have been firstly initiated at tertiary care hospitals in northern Thailand. Data collecting
on MDR/XDR-TB control has been tracked through the special project paper-based recording
and reporting systems set by the 10th Zonal Tuberculosis and Chest Disease Centre which
separated from the routine DOTS recording and reporting systems. Currently, a new computer
programme has been developed by staff of this centre to efficiently record and report the MDR/
XDR-TB data in the area of northern Thailand and attempt to gradually extend the use of this
computer programme throughout the country.
4. Presumptive diagnosis of MDR-TB
The Thailand’ s 2012 National Tuberculosis Management Guidelines [24] set the criteria for
probable or suspected MDR-TB, are :
1. patients with history of TB retreatment, especially within 6 months after completeness of
treatment or cure,
2. patients with interruption of 6 month-short course chemotherapy (2HRZE/4HR, H=iso‐
niazid, R=rifampicin, Z=pyrazinamide, E=ethambutol) and having continuously positive-
sputum smear examinations after treatment interruption,
3. patients with history of multiple TB treatments, irregular anti-TB drug taking, and
persistently positive-sputum smear examinations,
4. patients having positive-sputum smear examinations at the end of second and fifth
months of the 6-month short course chemotherapy (2HRZE/4HR),
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Figure 1. Mechanism of development of anti-tuberculosis drug resistance
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5. patients with evidence of HIV co-infection/AIDS before the 6-month short course chemo‐
therapy starting,
6. general TB patients with history of MDR-TB patient exposure, including health or medical
personnel with TB disease who have history of MDR-TB patient exposure, and
7. other high-risk patients of MDR-TB, such as general TB patient with huge lung cavity,
diabetic patients, prisoners with TB disease, and TB patients who live in the cross-
borderline areas.
5. Laboratory investigations for MDR-TB
Several plans have been announced for the WHO Stop TB Department to collaborate with the
Foundation for Innovative New Diagnostics (FIND) to initiate and introduce rapid-culture
technology and new rapid drug-resistant tests in the southern African countries and the world
including the international standards for the second-line drug-susceptibility testing [11]. The
Thailand’ s 2012 National Tuberculosis Management Guidelines [24] set the laboratory
investigations for MDR-TB which are direct acid-fast bacilli (AFB)-sputum smear examina‐
tions with sputum culture and drug susceptibility testing (DST). For reduction of the diagnosis
time for unrecognized drug-resistant TB, new rapid diagnostic technologies for drug resistance
from sputum smear or positive culture for smear-negative and extra-pulmonary TB must be
prioritized [10]. All TB control programmes in moderate- and high-MDR TB prevalent settings
should consider the promotion of culture and DST including implementation of use of
algorithms for the diagnosis of pulmonary and extra-pulmonary TB [10]. Rapid DST is
preferred to the conventional DST due to 1-2 days of resulting. Recently, the 2011 WHO
Guidelines recommends “ Xpert MTB/RIF® ” and line-probe assay which are new molecular
diagnostic technologies and can detect drug resistance to both isoniazid and rifampicin or only
rifampicin [24], but their disadvantage is inability to detect the resistance to every drugs used
in MDR-TB treatment for detecting probable XDR-TB, required expertise and expensive
technologies/equipments which limit their wider uses [25]. The conventional DST takes 1-3
months of the results that take markedly longer than the new molecular methods and is labor-
intensive [24]. Other alternative phenotypic methods based on the Mycobacterium tuberculosis
metabolism such as CO2 (carbon dioxide) production, oxygen uptake, ATP (adenosine
triphosphate) bioluminescence, etc. have been experimented and demonstrated promising in
overcoming this obstacle of longer time resulting [25]. These methods also have impressive
sensitivity and specificity compared to the conventional DST [25]. Currently, molecular line
probe assays and automated liquid culture systems are recommended by the WHO as the gold
standard for the first-line and second-line DSTs. Liquid culture DST has been demonstrated
to have relatively good reliability and reproducibility for aminoglycosides, fluoroquinolones,
and polypeptides for detecting XDR-TB [26]. However, liquid culture DST for other second-
line drugs such as para-aminosalisylic acid, linezolid, clarithromycin, amoxicillin-clavulanate,
cycloserine, clofazimine, terizidone, ethionamide, and prothionamide is not recommended by
the WHO [26]. A recent study reported the use of spoligotyping and sequence 6110 restriction
Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand
http://dx.doi.org/10.5772/54852
243
fragment length polymorphism insertion analysis of genomic DNA which demonstrated that
MDR-TB cases (74.0%) were more likely to be identified in clusters than anti-TB drug suscep‐
tible cases (33.6%) [27]. Xpert MTB/RIF assay recently has been introduced which meets the
requirements of effective diagnosis of pulmonary TB as the following : allowing detection of
both the Mycobacterium tuberculosis complex and resistance to the principal anti-TB drugs,
especially rifampicin (RIF or R), availability on a global scale with standardized-easy use and
robust diagnostic tools recently has been introduced [28]. This assay is a nucleic acid amplifi‐
cation test for detection of rifampicin resistance-associated mutations of the rpoB gene and
Mycobacterium tuberculosis complex DNA in sputum [28]. It can be designed for use with other
systems to automate and integrate sample processing, nucleic acid amplification, and detection
of target sequences using reverse transcriptase polymerase chain reaction (PCR) and real-time
PCR [28]. Between 2007-2009, the WHO has approved several drug-resistant TB diagnostic
tests such as liquid culture (MGIT®, an automated liquid culture, developed by BD Diagnostic
Systems, 2007) which has been used at the 10th Zonal Tuberculosis and Chest Disease Centre,
Chiang Mai, Thailand, line-probe assays (INNO-Lipa®, line-probe assay that requires culture,
developed by Innogenetics, 2008), noncommercial culture and drug susceptibility testing
(Microscopic Observation Drug Susceptibility (MODS), developed by Academic Laboratories,
2009; Nitrate reductase assay, developed by Academic Laboratories, 2009; and Colorimetric
drug susceptibility testing, developed by Academic Laboratories, 2009) [29]. GeneXpert MTB/
RIF®, a new automated nucleic acid amplification technique which was developed by
Cepheid, The Foundation for Innovative New Diagnostics (FIND) and University of Medicine
and Dentistry of New Jersey (UMDNJ) was reviewed by the WHO in 2011 [29] and currently
has been recommended to measure the Mycobacterium tuberculosis DNA and the rifampicin-
resistance sequence worldwide. This new technique has been set in Thailand at least 6 sets
including the one set at the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai,
Thailand in collaboration with the Unites States Centres for Disease Control and Prevention
(US-CDC) for reference laboratories in Thailand. GeneXpert test’s sensitivity is moderate at
67.2% in AFB-smear negative cases at one-time smear staining of the specimens, and increases
to 80% when is performed three times [28]. This test provides the results within two hours and
requires minimal training of the laboratory workers [29]. The limitations of the test are
requirement of a consistent source of electricity that will limit its use outside of the settings
where a regular electric power supply can be guaranteed, its expensive cost of the instrument,
and cost per test cartridge [29]. Mishra B et al. used the automated BACTEC 460 TB system in
study the emergence of drug-resistant TB at an urban tertiary care hospital in South India
which revealed that 37.2% were MDR-TB isolates whereas 42% of the pulmonary Mycobacte‐
rium tuberculosis isolates and 20.4% of extra-pulmonary isolates were MDR [30]. Phenotypic
and genotypic detections of anti-TB drug resistance are described as the following [31- 49]:
1. Phenotypic detection
1.1 Slide DST
This method has less equiptment, suitable for decentralization, 93% rifampicin susceptibility
at 88% predictive value of resistance.
1.2 Mycobacteria Growth Indicator Tube (MGIT) Systems
Tuberculosis - Current Issues in Diagnosis and Management244
This test has sensitivities of 100% for rifampicin, isoniazid, ethambutol and streptomycin,
specificity of 100% for rifampicin, 97.7% for isoniazid, 98.0% for ethambutol and 89.8%% for
streptomycin.
1.3 Microscopic observation broth-drug susceptibility assay (MODS)
This method has sensitivity of 72.7% and specificity of 99.7% for rifampicin, 72.6% and 97.9%
for isoniazid, and 77.8% and 99.7% for MDR-TB.
1.4 Mycobacteriophage-based method
1.4.1 Commercial FASTPlaque assay (FASTPlaque TB test and FastPlaque TB-
RIFTM (rifampicin DST) (Biotech Labs Ltd, Ipswich, UK))
This test has sensitivity and specificity of 31.2% and 94.9%, respectively in all anti-TB drug-
susceptible and resistant TB patients, sensitivity and specificity of 33.3% and 93.9%, respec‐
tively in all anti-TB drug-susceptible and resistant TB patients with HIV-infection/AIDS.
1.4.2 Fluoromycobacteriophage assay (Figures 2, 3)
This method has 94% sensitivities for rifampicin and isoniazid and 98% sensitivity for
streptomycin and specificities of 97% for isoniazid, 95% for rifampicin, and 98% for strepto‐
mycin (resazurin microplate technique), sensitivity of 94% for all three anti-TB drugs (rifam‐
picin, isoniazid, and streptomycin) (EGFP-phage technique) and specificities of 93% for
rifampicin, 90% for isoniazid and 95% for streptomycin (EGFP-phage technique).
1.4.3 Luciferase reporter phage assay
This test has 100% sensitivity and 89-100% specificity for culture isolates.
1.5 Nitrate reductase assay
This method has sensitivity and specificity of 100% and 100% for rifampicin, 93% and 100%
for isoniazid, 76% and 100% for streptomycin, and 55% and 99% for ethambutol, respectively.
1.6 Microcolony method (Thin-layer agar (TLA) method)
This test has sensitivities and specificities of 100% for both rifampicin and ofloxacin, and
sensitivity of 100% and specificity of 98.7% for kanamycin, 100% overall accuracy for rifam‐
picin and isoniazid resistance.
1.7 Colorimetric redox indicator methods
This method has sensitivities of 100% for rifampicin, ofloxacin, kanamycin and capreomycin
and 99.1% for isoniazid, specificity of 100% for rifampicin, isoniazid, ofloxacin and kanamycin,
and 97.9% for capreomycin, overall accuracy of 98.4% for rifampicin, 96.6% for isoniazid, 96.7%
for ofloxacin, 98.3% for kanamycin and 90% for capreomycin.
2. Genotypic detection (Nucleic Acid Amplification)
2.1 Line-probe assay (LPA)
2.1.1 INNO-LiPA Rif.TB® assay (Innogenetics, Ghent, Belgium)
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This test has higher than 95% sensitivity and 100% specificity, sensitivity of 82.2% and
specificity of 66.7% for MDR-TB detection.
2.1.2 GenoType® MTBDRplus kit (Hain Lifescience, Nehren, Germany)
This method has nearly 91% sensitivity for MDR-TB, possibly detects rifampicin and isoniazid
resistance and confirms TB infection simultaneously.
2.1.3 Genotype MTBDRsl assay
This test has ethambutol, 89% sensitivity for ofloxacin, 87% sensitivity for capreomycin, 75%
sensitivity for amikacin.
2.2 Real-time PCR
This technique has sensitivity of 89% and specificity of 99% (molecular beacons), overall
sensitivity of 98-100% with 72% sensitivity in smear-negative specimens and specificity of
100% for Xpert MTB/RIF assay (Cepheid Xpert MTB/RIF®, Sunyvale, CA).
2.3 PCR sequencing
This technique has sensitivities of 96.7% for rifampicin-resistant isolates (rpoB gene), 64% for
isoniazid-resistant isolates (katG gene) and 70% of ofloxacin-resistant isolates (gyrA gene) (PCR
pyrosequencing).
2.4 DNA Microarrays (DNA biochip)
This technique has specificity of 97% and 95% for rifampicin, 91% and 60% for isoniazid,
96%  and  67%  for  kanamycin,  93%  and  73%  for  streptomycin,  and  98%  and  89%  for
ethambutol,  respectively,  simultaneous detection of  multiple  genetic  sequences (oligonu‐
cleotide microarray).
Although genotypic methods have potentially fastest results, the massive cross-contamination
is still the main risk. To prevent its, strict internal controls, special technique, and separation
of working areas are required. The reproducibility of the results of the Xpert MTB/RIF assay
under actual field conditions, the strength of the laboratories, and the manner and extent of
its introduction are the impact of this new assay. The sources of error for genotypic methods
are incomplete coverage of rifampicin-resistance gene-core region and mixtures (multiple
mutations, wild-type strain/emerging mutant) and silent mutations. These sources of error
may contribute to 1% false-resistant and 5% false-susceptible results [31].
Schematic  representation of  phAE87  :  hsp60-EGFP  construction.  Shuttle  phasmid phAE87
is  a  conditionally  replicating  derivative  of  phage  TM4  in  which  the  cosmid  moiety  is
flanked by Pac I restriction sites. A plasmid derivative of pYUB854  containing the EGFP
gene (pMP14) was used to replace the cosmid in phAE87  followed by lambda packaging
and recovery in E. coli.
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Source : Rondo′n L, Piuri M, Jacobs WR Jr, Waard Jde, Hatfull GF, Takiff HE. Evaluation of fluoromycobacteriophages
for detecting drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2011; 49 (5) : 1838-1842.
Figure 3. A, B). Two strains of Mycobacterium tuberculosis were incubated separately in 7H9-OAD with 2 µg of rifam‐
picin/ml for 24 hours, infected with the EGFP-phage, killed with paraformaldehyde, and then fixed on microscope
slides. The images, obtained with a fluorescence microscope, show a susceptible-to-rifampicin strain (A) and a resist‐
ant-to-rifampicin strain (B).
Source : Piuri M, Jacobs WR Jr, Hatfull GF. Fluoromycobacteriophages for rapid, specific, and sensitive antibiotic sus‐
ceptibility testing of Mycobacterium tuberculosis. PLoS ONE 2009; 4(3) : e4870. doi: 10.1371/journal.pone.0004870
Figure 2. Fluoromycobacteriophages construction
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6. Radiological features in patients with MDR/XDR-TB
A recent study in South Korea showed 100% of lung nodules, 60% of lung consolidation,
and 47% of lung cavities that were mainly located in the upper and middle lung zones
in XDR-TB patients whereas less frequent lung nodules and ground-glass opacity lesions
were found in XDR-TB patients  compared to the patients  with anti-TB drug-susceptible
pulmonary TB [50]. More frequent multiple lung cavities, lung nodules, and bronchial di‐
latation  were  found  in  both  MDR-TB  and  XDR-TB  patients  compared  to  the  patients
with  anti-TB  drug-susceptible  pulmonary  TB  [50].  There  was  no  different  radiological
findings between MDR-TB and XDR-TB patients [50]. Another recent study in South Ko‐
rea  revealed  that  micronodules  and tree-in-bud appearance  were  found in  100% of  the
pulmonary  XDR-TB  patients  whereas  lung  consolidations,  lung  cavities,  bronchiectasis,
lobar consolidations were found in 85%, 85%, 80%, and 70%, respectively [51]. This study
showed  a  significantly  larger  extent  of  tree-in-bud  appearance  and  lung  consolidations
compared to the MDR-TB patients [51]. In childhood patients, chest radiological features
at the time of diagnosis demonstrates lobar opacification, intrathoracic lymphadenopathy,
particular  hilar  lymph nodes,  and airway narrowing [52].  Chest  radiological  features  of
three patients with MDR-TB who attended the 10th Zonal Tuberculosis and Chest Disease
Centre,  Chiang Mai,  Thailand are shown in the Figure 4  (A,B,C) which demonstrated a
single cavity at the upper lung zone in two patients and no lung cavity in another one.
These  three  patients  possibly  attended  the  10th  Zonal  Tuberculosis  and  Chest  Disease
Centre, Chiang Mai, Thailand at the earlier stages compared to the above study results.
 
 
 
 
 
 
 
 
 
 A B C 
Figure 4. First-attendance chest radiological features of the three patients (A,B,C) with MDR-TB at the 10th Zonal Tu‐
berculosis and Chest Disease Centre, Chiang Mai, Thailand A : Showing bilaterally diffuse lung infiltration with a cavity
in the left upper lung zone, B : Showing fibrotic infiltration with surrounding new infiltration at the right upper lung
zone with bilaterally diffuse emphysematous lung changes, C : Showing bilaterally diffuse infiltration with a cavity in
the right upper lung zone with left pleural effusion.
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7. Regimens used in treating patients with drug-resistant tuberculosis
A recent study on MDR-TB treatment revealed that use of later generation quinolones
(moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin), ofloxacin or ethionamide/prothiona‐
mide, use of four or more likely effective drugs in the initial intensive phase, and three or more
likely effective drugs in the continuation phase was associated with the treatment success
compared to the treatment failure or relapse [53]. The duration of initial phase up to 7.1-8.5
months and the total duration of treatment up to 18.6-21.5 months increased the chances of
treatment success [53]. In 2011, the WHO recommended the regimens containing a fluoroqui‐
nolone, pyrazinamide, ethionamide (or prothionamide), para-aminosalicylic acid (or cyclo‐
serine), and a second-line injectable drug with more than 20 months of treatment duration [54].
Five MDR-TB control projects with used DST results and previous treatment history were
conducted among 1,047 MDR-TB patients in 5 resource-limited settings with well-established
DOTS programmes (Manila, Estonia, Latvia, Lima, and Tomsk) in 1999 for Lima and Manila,
2000 for Tomsk and Latvia, and 2001 for Estonia [55]. At least 4 drug (ethambutol, pyrazina‐
mide, cycloserine, clofazimine, para-aminosalicylic acid, ethionamide, or prothionamide,
augmentin, clarithromycin or thiacetazone) including an injectable drug (kanamycin, amika‐
cin, capreomycin, or streptomycin) and a fluoroquinolone (ofloxacin, ciprofloxacin, or
levofloxacin) were administered for the duration of treatment (18-24 months) except for the
injectable drug, which was administered for a specified interval after the patient’ s specimens
were culture-negative [55]. Monthly sputum-AFB smear and culture were monitored [55].
Every 6-months (Manila and Lima) and 3-months chest radiographs (Tomsk, Latvia, and
Estonia) were performed [55]. The treatment outcomes among new and previously treated
MDR-TB patients revealed 74.8% and 68.3% cured patients, 2.5% and 0.3% completed treat‐
ment patients, 4.2% and 7.0% failed treatment patients, 3.4% and 14.2% dead patients, and
77.3% and 66.6% treatment success rates (cure rate + completed treatment rate), respectively
[55]. The results showed worsen outcomes among previously treated patients. Report from
the 10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand, in 2011 which
had been collected from the data of laboratory-confirmed 254 MDR-TB patients (72.8% of all
probable MDR-TB cases) among 349 totally suspected-MDR-TB cases with 15.8% of HIV co-
infection in northern Thailand between 2005-2010 gradually increased from 62.2% of probable
MDR-TB cases in 2005 to 78.3% in 2010 and revealed 3.2% treatment-denial patients, 75.2%
treatment-registered patients, 30.2% died before starting the second-line drug treatment
regimens (pyrazinamide, ethambutol, ofloxacin, para-aminosalicylic acid administered for
18-24 months and one injectable drug (kanamycin, or amikacin) administered 5 days per week
for the initial 6-month phase), 25.4% default-treatment patients (continuous interruption of
treatment more than 2 months), 54.8% treatment success rate, and 22.2% unavailable-data
patients [7]. Among 19 cases with pre-treatment death, 10 cases (52.63%) demonstrated HIV
co-infection. Extra-pulmonary cases accounted for 2.4% of the laboratory-confirmed cases
which was lower than percentage of susceptible extra-pulmonary TB cases in the same area
[56]. Four cases with laboratory-confirmed MDR-TB emerged as XDR-TB during treatment [7].
A previous study on outcomes of a daily supervised-MDR-TB treatment regimen which
consisted of initial phase of 6-9 months with kanamycin, ofloxacin, cycloserine, ethionamide,
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ethabutol, and pyrazinamide demonstrated that in cases of persistent culture positive at fourth
month, the initial phase was extended for additional 3 months. Then ofloxacin, cycloserine,
ethionamide, and ethambutol were continued for 18 months [57]. The results of the study
revealed that 82% of cases demonstrated time to culture conversion at the second month or
before. The culture conversion rates at third month and sixth month were 84% and 87%,
respectively. The cure rate was 66%. At 24 months, 79% of the patients remained culture
negative for more than 18 months. Adverse drug reactions were reported among 58% of cases
and 2 failure cases emerged as XDR-TB during treatment [57]. A recent study on comparison
between traditional hospital-based treatment-model of MDR-TB patient care and community-
based model in rural areas of South Africa revealed that median times to starting the treatment
and sputum smear conversion were shorter for community-based model (84 days versus 106.5
days and 59 days versus 92 days, respectively) [58]. Lack of sputum culture conversion at
month 9 was a predictor of pulmonary MDR-TB treatment failure with 84% of sensitivity and
94% of specificity [59]. A recent study by Dheda K et al. demonstrated that the number of XDR-
TB deaths was not significantly different compared between patients with and without HIV
co-infection [60] whereas Well CD recently reported that lower cure rates and higher death
rates were found in MDR-TB patients with HIV co-infection compared to the patients without
HIV co-infection [61]. Survival of XDR-TB patients with HIV co-infection was associated with
absence of biomarkers indicative of multiorgan dysfunction, less advanced stage of both
diseases at time of diagnosis, and antiretrovirals provision [62]. Previous culture-proven MDR-
TB, number of drug used in a MDR-TB treatment regimen, and treatment with moxifloxacin
were independent predictors of death [60] while some previous reports showed that treatment
success rates were poor (30-50%) in XDR-TB patients with HIV co-infection [63] and the MDR/
XDR-TB prevalence was substantially precipitated by the HIV epidemic [64, 65]. In children
with MDR-TB, the treatment guidelines are the same principles, using the same drugs as in
adult patients with strict and prolonged supervision by expert pediatricians [66]. HIV co-
infection are particular challenges and requires early starting of antiretroviral therapy with
careful monitoring for drug-adverse side-effects [66]. Children with close contact with MDR-
TB patients should be tested with tuberculin skin testing or interferon-gamma release assays,
direct AFB-smear examinations, cultures, and DST and taking the chest radiological exami‐
nations [24]. Cases with close contact should be at least 2-year followed up [24]. If they are
diagnosed MDR-TB, they must be treated with the empirical MDR-TB regimen [24]. Empirical
MDR-TB treatment regimen is not recommended for MDR-TB chemoprophylaxis [24]. MDR-
TB chemoprophylaxis for children with at least 2 second-line drugs for 6-12 months and
reflecting the susceptibility profile of the source case’ s isolate with daily supervision should
be considered [52, 67]. The knowledge of mechanisms of the second-line drugs for children is
necessary for ensuring the treatment adherence and long-term control of the disease.
A previous study on the second-line drug susceptibility among 40 MDR-TB strains in Turkey
revealed mono-resistant to ethionamide 25%, amikacin 10.0%, kanamycin 2.5%, ofloxacin
2.5%, amikacin 0%, and clofazimine 0%, any resistant to ethionamide 37.5%, capreomycin
25.0%, kanamycin 5.0%, ofloxacin 5.0%, amikacin 5.0%, and clofazimine 2.5%, resistant to both
ethionamide + capreomycin 5.0%, both capreomycin + clofazimine 2.5%, ofloxacin + ethiona‐
mide + capreomycin 2.5%, amikacin + ethionamide + capreomycin 2.5%, and kanamycin +
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amikacin + ethionamide + capreomycin 2.5% [68]. Currently, the data of the second-line drug
resistance are not available [9].
The Thailand’ s 2012 National Tuberculosis Management Guidelines [24] recommends the
guidelines for both pulmonary and extra-pulmonary MDR-TB treatment as the following flow
diagram :  
 
 
 
 
   
 
 
 
                                                                                                       
           
 
 
 
 
       
 
 
 
 
 
       
 
 
 
Probable/Suspected  MDR-TB If  dramatic  response  to  the  regimen 
2HRZE/6HR, continue  2HRZE/4HR (2  
months  of  rifampicin (R), isoniazid (H), 
pyrazinamide (Z), and  ethambutol (E), 
followed  by  4  months  of  R  and  H) 
If  previous  treatment  outcome  showed  failure  to  the  
regimen  2HRZE/4HR, prescribe  the  empirical  MDR-
TB  treatment  regimen  
8K5-7(PAS)(Eth)(Lfx)(Cs)/12(PAS)(Eth)(Lfx)(Cs) 
(Note : 8  months  of  kanamycin (K, 5-7  doses  per  
week), para-aminosalicylic  acid (PAS), ethionamide 
(Eth), levofloxacin ((Lfx), cycloserine (Cs), and  
followed  by  12  months  of  PAS, Eth, Lfx, and Cs)   
Performing  DST  for  R, H, Z, E, S  for  
exclusion  of  Non-TB  mycobacteria 
(very  few  centres  in  Thailand  can  
perform  the  DST  for  pyrazinamide) 
During  waiting  for  the  DST  results  and  previous  
treatment  outcome  showed  relapse  TB, prescribe  
the  regimen  2SHRZE/1HRZE/5HRE 
(Note : 2  months  of  streptomycin (S), isoniazid (H), 
rifampicin (R), pyrazinamide, and  ethambutol (E), 
followed  by  1  month  of  H, R, Z, and  E, and  
followed  by  5  months  of  H, R, and  E)   
If  know  DST  results, the  treatment  regimen  
used  depends  on  clinical  responses, AFB-
smear  examination  results, and  DST  results 
Figure 5. Flow Diagram of Management of Patient with Probable/Suspected MDR-TB
Currently, in Thailand, patients with persistent AFB-smear and/or culture positive after
completeness of MDR-TB treatment will be prescribed isoniazid alone for lifelong while no
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standardized treatment is recommended yet. Types of patients with MDR-TB, patient moni‐
toring during MDR-TB treatment and assessment of sputum conversion, and classification of
treatment outcomes are shown in the Table 1, 2, and 3, respectively [24].
Type Description
New case patient who does not take any anti-TB drugs before or take any anti-TB drugs less than 1 monthduration and the DST results show resistance to at least rifampicin and isoniazid
Relapse case patient who cured of MDR-TB in the past and present or pre-treatment of relapse-MDR-TB DSTresults reveal MDR-TB
After default MDR-
TB
patient who continuously interrupts the TB treatment more than 2 months and the DST results
before treatment interruption demonstrates MDR-TB
After failure of the
first- TB treatment
patient’ s AFB examinations show positive results at the end of the fifth month and the DST
results at the end of the second or fifth month reveal MDR-TB
After failure of
retreatment
patient who treated with the retreatment regimen (2 months of streptomycin, rifampicin,
isoniazid, pyrazinamide, and ethambutol, followed by 1 month of rifampicin, isoniazid,
pyrazinamide, and ethambutol , and then followed by 5 months of isoniazid, pyrazinamide, and
ethambutol for relapse cases) and the DST results at the end of third or fifth month demonstrate
MDR-TB
Transfer in
patient who is referred from one setting to the other setting for further diagnosis, treatment,
and management, transferred setting must report the outcome of treatment to the referred
setting (first setting) for discharge registration as “ transfer in ”
Other
other patients who cannot be registered as the above 6 patient-registration types including
patients who treated with empirical MDR-TB treatment regimen at the non-NTP settings (not
registered as the above 6 patient-registration types)
Table 1. Registration of the patients with MDR-TB [24]
Patient monitoring during MDR-TB treatment Assessment of sputum conversion
Direct AFB-smear examinations and cultures will be
performed at month : 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, , 14,
16, 18, and 20.
Results of 2 consecutively direct-AFB-smear negative and
culture negative with 30-day intervals will indicate sputum
conversion. Mostly, patients with sputum conversion will
converse the positive to the negative results within the first 6-
month of treatment duration.
Chest radiological examinations will be performed at
month : 0, 3, 6, 12, and 18.
Table 2. Patient monitoring during MDR-TB treatment and Assessment of sputum conversion [24]
8. Patient monitoring after completeness of the MDR-TB treatment [24]
For assessment of the MDR-TB relapse rate, direct AFB-smear examinations and cultures are
performed and assessed every 3 months in the first 6-month completeness of treatment and
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then every 6 months for 18 months. Chest radiological examinations are preformed when
indicated.
Cured
patient who treated with MDR-TB treatment regimen following the Thailand’ s 2012 National
Tuberculosis Control Management (or NTP) Guidelines with consecutively 5- negative results of the
30 day-interval AFB smear examinations and cultures of the last 12 months of treatment duration
Treatment
completed
patient with completeness of the MDR-TB treatment following the Thailand’ s 2012 NTP
Guidelines but no consecutively AFB-smear examination and culture results during the last 12-
month treatment duration
Died patient with any cause of death during MDR-TB treatment following the Thailand’ s 2012 NTPGuidelines
Failed
patient treated with MDR-TB regimen following the Thailand’ s 2012 NTP Guidelines with 2
positive results of the 5 consecutive AFB-smear examinations and cultures during the last 12
months of treatment duration or patient with 1 positive-culture result of the last 3 consecutive
cultures or patient with physician’ s decision to stop the MDR-TB treatment due to clinical
unresponsiveness or various adverse-drug reactions
Default patient with continuous interruption of the MDR-TB treatment following the Thailand’ s 2012 NTPGuidelines
Transfer out partially MDR-TB treated patient with referring from (Transferring out) one setting to anothersetting with unknown treatment outcomes will be registered as “ Transfer out ”
Table 3. Classification of treatment outcomes [24]
9. MDR-TB management and treatment outcomes in Thailand between
2007-2009
The prevalence of laboratory-confirmed MDR-TB was 0.08%. Highest prevalence (0.21%) was
found in the central part of Thailand. MDR-TB was mostly diagnosed and treated at the
secondary care settings or general hospitals (31.5% and 31.14%), 24.3% and 25.08% of cases
were diagnosed at the tertiary care settings and only 6.9% and 6.7% of the patients were
diagnosed at the university hospitals, respectively [9]. The majority of the patients (63.82%)
were registered as “ after failure of the first-TB treatment ” [9]. In Thailand, numbers of the
secondary care settings or general hospitals are more than that of the tertiary care hospitals,
this may reflex the above figures. Only 33.5% of cases were referred to the well-facilitated
setting for directly observed treatment (DOT) [9]. Only 60.6% of MDR-TB cases were prescri‐
bed 4 oral second-line drugs and an injectable aminoglycoside drug [9] which recommended
by the Thailand’ s 2012 National Tuberculosis Management Guidelines while the rests were
prescribed various treatment regimens [24]. Only 57.5% of cases had completed treatment
adherence [9]. Low DOT implementation can contribute to high default rates, high treatment
failure rates, high death rates, and low cured rates. There was 24.2 % of patients with com‐
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pleteness of treatment, 29.1% cured, 20.5% default, 2.2% treatment failure, and 21.5% died [9].
Treatment failure and treatment default rates were higher among new case compared to the
patients with previous TB treatment whereas higher death rates were found among the
patients with previous TB treatment. This could be due to inadequately strict- and intensive-
health education provision to the new cases and more severe disease at the time of diagnosis
among the patients with previous TB treatment. Only 27.5% of cases with completed treatment
were followed up more than 2 months [9].
A recent study in South Korea revealed that the treatment regimen was individualized based
on the history of anti-TB drugs taken by the patient and the most DST result [69]. Three to
seven anti-TB drugs were self-administered except injectable drugs during hospitalization
[69]. Injectable drugs were prescribed for 6-7 months [69]. The total treatment duration was at
least 18 months after sputum culture conversion [69]. If the medical treatment was expected
to fail or had failed in patients with localized lung cavities, or bilateral lesions and anticipated
adequate postoperative lung function, surgical resection was considered [69]. The treatment
outcomes showed that 37.1% of patients had treatment success, and 4.5% of them died of all
causes during the 3-4 years after treatment initiation [69]. The independent predictors of all-
cause mortality were age, history of MDR-TB treatment, XDR-TB, and prothionamide resist‐
ance [69]. Currently, there is no DOTS programme implementation in South Korea [69] while
Thailand has been implemented several years ago, but the treatment outcomes were better
than that of Thailand [9, 69]. These different results of both projects should be intensively
investigated and explained. Kliiman K et al. recently demonstrated that predictors of poor
treatment outcomes in MDR-TB were previous TB treatment, ofloxacin resistance, positive-
AFB smear, and HIV-infection/AIDS [70].
The criteria for capacity of establishment of the specialized MDR-TB centre that recommended
by the Thailand’ s 2012 NTP guidelines [24] are as the following : 1.authorized persons’
recognition of the MDR-TB threats 2.good laboratory networks and good patient-referral
system 3.good DOT system, and 4.consistently continuous care for MDR-TB patients.
10. XDR-TB treatment
A previous study in Peru by Mitnick CD et al. demonstrated that 48 (7.4%) of 651 tested-isolate
patients had XDR-TB [71]. The results showed various individualized regimens prescribed for
47 patients with XDR-TB as the following : 1) 14.9% of the patients included ethambutol, 2)
34.0% included pyrazinamide, 3) 38.3% included streptomycin, 4) 19.1% included amikacin,
5) 53.2% included capreomycin, 6) 17.0% included kanamycin, 7) 21.3% included ciprofloxacin,
8) 12.8% included ofloxacin, 9) 42.6% included levofloxacin, 10) 2.1% included spafloxacin, 11)
72.3% included moxifloxacin, 12) 100% included cycloserine, 13) 66.0% included ethionamide,
14) 95.7% included para-aminosalicylic acid, 15) 100% included amoxicillin-clavulanate, 16)
44.7% included clarithromycin, 17) 97.9% included clofazimine, 18) 17.0% included rifabutin,
19) number of drugs in regimen (number without documented resistance or prior exposure
for more than 1 month) : 19.1) 5.3 +/- 1.3 agents among all available agents, 19.2) 3.2 +/- 1.2
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agents among 12 agents or classes for which routine DST was performed, 20) median duration
of treatment with injectable agents : 15.4 months, and 21) median duration of treatment ranged
8.0- 24.9 months, median duration from treatment initiation to surgery : 11.6 months, and
median duration of treatment for patients undergoing surgery : 31.2 months [70]. The median
duration of follow-up was 19.4 months [71]. Treatment outcomes revealed that 60.4% of
patients were cured or completed treatment [71]. This study is currently the up-to-date
information of XDR-TB treatment. Positive AFB-smear, and urban residence could be predic‐
tors of poor treatment outcomes in XDR-TB [70]. For patients with mono/poly-resistant drug
(s) TB, the recommended treatment regimens are shown in the Table 4 (13).
Mono/Poly-resistant Drug (s) Regimen
Rifampicin mono-resistance
initial 2 months of isoniazid, pyrazinamide, and ethambutol, and followed by
10-16 months of isoniazid, ethambutol and a fluoroquinolone +/- initial 6
months of an injectable drug
Isoniazid mono-resistance
initial 2 months of rifampicin, pyrazinamide, and ethambutol, and followed
by 4-7 months of rifampicin, and a fluoroquinolone (750-1,000 mg of
levofloxacin or 400 mg of moxifloxacin substituted for isoniazid in the
standard 6-month short-course regimen)
Rifampicin and pyrazinamide (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, ethambutol, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Rifampicin and ethambutol (+/-
streptomycin) resistance
at least the initial 2-3 months of isoniazid, pyrazinamide, a fluoroquinolone,
and an injectable drug (initial 6 months if extensive disease) for 18 months of
total treatment duration
Isoniazid and pyrazinamide resistance 9-12 months of rifampicin, ethambutol,and a fluoroquinolon (longer ifextensive disease)
Isoniazid and ethambutol resistance 9-12 months of rifampicin, pyrazinamide, and a fluoroquinolone (longer ifextensive disease)
Isoniazid, pyrazinamide, and ethambutol
(+/- streptomycin) resistance
at least the initial 2-3 months (6 months if extensive disease) of rifampicin, a
fluoroquinolone, an oral second-line drug, an injectable drug for 18 months
of total treatment duration
Table 4. Treatment of patients with mono-drug resistant and poly-drug resistant tuberculosis [13]
11. MDR/XDR-TB treatment-pipeline agents or compounds in clinical
trials and related innovative researches
Currently, drugs in phase III clinical trials are moxifloxacin, gatifloxacin, and meropenem [72].
Heteronemin, nephalsterol, litosterol, and kahalalides are other interesting compounds which
are in pre-clinical stage [72]. Okada M et al. conducted a study on granulysin and a new DNA
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vaccine against MDR/XDR-TB and revealed that agglutinating virus of Japan/Heat-Shock-
Protein65DNA+Interleukin-12-12DNA vaccine provided strong therapeutic efficacy in killing
MDR/XDR-TB bacilli in mice and monkey models [73]. A recent experiment using MDR-TB
monkey models which received normal and genetically altered Bacilli Calmette Gue′rin (BCG)
vaccines demonstrated that these 2 groups of monkeys survived well compared to the control
group [74]. Another study in XDR-TB mice model showed ability of interleukin-7 to kill the
bacilli [74].
12. Totally drug-resistant tuberculosis
Totally drug-resistant tuberculosis (TDR-TB or XXDR-TB) was recently defined as TB bacilli
which resist to all first-line and the 6 second-line drugs (para-aminosalicylic acid, fluoroqui‐
nolones, aminoglycosides, thiamines, polypeptides, and cycloserine) [75]. Meanwhile, a recent
report from the US-CDC listed 7 challenges that should be addressed before new terminology
of TDR-TB should be considered for adopting [76], following are the challenges:
1. The definition should not hinge on resistance to all drugs tested, because the number of
drugs tested varies widely between laboratories.
2. In vitro testing data suggest cross-resistance among different drugs within a class of drugs
or closely related classes of drugs (e.g., polypeptides and aminoglycosides) is not 100%.
3. Research and reference laboratories in many countries do not test for resistance to the
third-line drugs (linezolid, thioridazine, other phenothiazines, monobactams (merope‐
nem, imipenem), macrolides, metronidazole and other imidazoles, clofazimine, and
amoxicillin/clavulanic acid).
4. DST for several anti-TB drugs is not sufficiently reliable or reproducible; retesting the
same isolate provides a different result in many cases.
5. There are several new anti-TB agents in development pipeline that will be prototypes for
new classes of antimycobacterial drugs or add new chemical entities to existing class.
6. Avoiding the unintended implication that patients with TDR-TB should not or cannot be
treated.
7. Global laboratory capacity for DST of Mycobacterium tuberculosis isolates remains limited
[75]. Two cases of TDR-TB with controversies of terminology and treatment occurred in
2003 in Italy and firstly reported in 2007 [77]. Currently, in Thailand, patients with all anti-
TB drug-resistance will be prescribed isoniazid alone for lifelong whereas no standardized
treatment is recommended yet. During 21-22 March 2012, the WHO had convened a
technical consultation to discuss the feasibility and implications of a definition to cover
more advanced patterns of TB resistance than XDR-TB [78]. The WHO concluded that
reports of severe patterns of anti-TB drug resistance ( worse than XDR-TB alone) are
increasing whereas a new definition of anti-TB drug resistance beyond XDR-TB is not
recommended [78]. This undefined resistance patterns contributed to technical difficulties
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with DST of several anti-TB agents, the lack of standardized DST methods for several
present and new investigational drugs, and insufficient evidence to link such DST results
to patients’ treatment outcomes [78]. No DST methods for group 5 and new investigational
agents currently exist [78]. Molecular DST for the second-line drugs cannot yet replace
phenotypic methods [78]. Collaboration between the national TB control programme,
Ministries of Public Health, and the pharmaceutical companies will be required to resolve
the limitations of treatment options by the compassionate use of new anti-TB agents [78].
The WHO will be the lead in ensuring that better patient data provide a more robust
information for future policy decision [78].
13. Conclusion
As countries are purchasing and using second-line drugs, the likelihood of misuse and
developing of TB-resistant strains increases. Currently, WHO and its partners have reached
the phase of expanding MDR-TB control as a component of a comprehensive TB control
programme. Launching in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM) expected that requests for second-line drugs for MDR-TB management should go
through the Green Light Committee to prevent their misuse. The number of Green Light
Committee-approved MDR-TB control programme is increasing rapidly as a result of main
streaming of MDR-TB management into general TB control efforts. Expanding projects and
accelerating evidence gathering are essential to further develop international policies. The TB-
endemic countries themselves and the ability of the technical agencies, as well as the donor
community are the factors of future success to expand MDR-TB control programmes.
Author details
Attapon  Cheepsattayakorn*
Address all correspondence to: attaponche@yahoo.com
10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, 10th Office of Disease Pre‐
vention and Control, Chiang Mai, Department of Disease Control, Ministry of Public Health,
Thailand, Thailand
References
[1] The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance.
Anti-tuberculosis drug resistance in the world 1999-2002. Third Global Report.
Communicable Diseases. Geneva : World Health Organization ; 2003.
Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand
http://dx.doi.org/10.5772/54852
257
[2] The Bureau of Tuberculosis of Thailand’ s Project on Anti-tuberculosis Drug Resistance
Surveillance. Anti-tuberculosis drug resistance in Thailand 1997-1998. First Country
Report. Nonthaburi, Thailand : Department of Disease Control, Ministry of Public
Health; 1999.
[3] The Bureau of Tuberculosis of Thailand ‘ s Project on Anti-tuberculosis Drug Resistance
Surveillance. Anti-tuberculosis drug resistance in Thailand 2001-2002. Second Country
Report. Nonthaburi, Thailand : Department of Disease Control, Ministry of Public
Health; 2003.
[4] The Bureau of Tuberculosis of Thailand ‘ s Project on Anti-tuberculosis Drug Resistance
Surveillance. Anti-tuberculosis drug resistance in Thailand 2005-2006. Third Country
Report. Nonthaburi, Thailand : Department of Disease Control, Ministry of Public
Health; 2007.
[5] Tuberculosis Annual Report-2008. Bangkok, Thailand : The Bureau of Tuberculosis of
Thailand ; 2009.
[6] Tuberculosis Annual Report-2003. Bangkok, Thailand : The Bureau of Tuberculosis of
Thailand ; 2004.
[7] Tuberculosis Annual Report-2011. Chiang Mai, Thailand : Tenth Zonal Tuberculosis
and Chest Disease Centre, Tenth Office of Disease Prevention and Control, Chiang Mai,
Thailand; 2012.
[8] Tuberculosis Annual Report-2009. Chiang Mai, Thailand : Tenth Zonal Tuberculosis
and Chest Disease Centre, Tenth Office of Disease Prevention and Control, Chiang Mai,
Thailand; 2010.
[9] The Bureau of Tuberculosis of Thailand ‘ s Research Project on Anti-tuberculosis Drug
Resistance Surveillance. Situation of Multidrug-Resistant Tuberculosis in Thailand :
Fiscal Year 2007-2009. Country Report. Nonthaburi, Thailand : Department of Disease
Control, Ministry of Public Health; 2010.
[10] Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-
infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc
Lung Dis 2008; 12 (12) : 1370-1375.
[11] Jain A, Dixit P. Multidrug-resistant to extensively drug-resistant tuberculosis : what is
next? J Biosci 2008 ; 33 (4) : 605-616.
[12] Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis : clinical and
molecular perspective. Antimicrob Agents Chemother 2002; 46 (2) : 267-274.
[13] Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist 2011;
4: 129-135.
[14] Prasad R. Management of multidrug-resistant tuberculosis : practitioner’ s view point.
Indian J Tuberc 2007; 54 (1) : 3-11.
Tuberculosis - Current Issues in Diagnosis and Management258
[15] Liu CH, Li HM, Li L, Hu YL, Wang Q, Yang N, et al. Anti-tuberculosis drug resistance
patterns and trends in a tuberculosis referral hospital, 1997-2009. Epidemiol Infect 2011;
139 (12) : 1909-1918.
[16] Chakroborty A. Drug-resistant tuberculosis : an insurmountable epidemic ? Inflam‐
mopharmacology 2011; 19 (3) : 131-137.
[17] Arnadottir T. The Styblo model 20 years later : what holds true ? Int J Tuberc Lung Dis
2009; 13 (6) : 672-690.
[18] Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, et al. Risk factors
for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int
J Tuberc Lung Dis 2012; 16 (1) : 90-97.
[19] Marahatta SB. Multidrug-resistant tuberculosis burden and risk factors : an update.
Kathmandu Univ Med J (KUMJ) 2010; 8 (29) : 116-125.
[20] Banerjee R, Schecter GF, Flood J, Porco TC. Extensively drug-resistant tuberculosis :
new strains, new challenges. Expert Rev Anti Infect Ther 2008; 6 (5) : 713-724.
[21] Prasad R. Multidrug and extensively drug-resistant TB (M/XDR-TB) : problems and
solutions. Indian J Tuberc 2010; 57 (4) : 180-191.
[22] Blomberg B. Antimicrobial resistance in developing countries. Tidsskr Nor Laegeforen
2008; 128 (21) : 2462-2466.
[23] Eurosurveillance editorial team. New WHO Europe Action Plan to fight MDR-TB.
http//www.eurosurveillance.org/ViewArticle.aspx?Articleld=199967 (accessed 4
August 2012).
[24] The Thailand’ s 2012 National Tuberculosis Management Guidelines. Bangkok,
Thailand : The Bureau of Tuberculosis of Thailand; 2012.
[25] Singh P, Katoch VM. Multidrug-resistant tuberculosis : current status and emerging
tools for its management in India. J Commun Dis 2006; 38 (3) : 216-229.
[26] O’ Grady J, Maeurer M, Mwaba P, Kapata N, Bates M, Hoelscher M, et al. New and
improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr
Opin Pulm Med 2011; 17 (3) : 134-141.
[27] Nodieva A, Jansone I, Broka L, Pole I, Skenders G, Baumanis V. Recent nosocomial
transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J
Tuberc Lung Dis 2010; 14 (4) : 427-433.
[28] Bodmer T, Str hle A. Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test.
J Vis Exp 2012; 9 (62) : e3547. DOI : 10.3791/3547
[29] Syed J. The tuberculosis diagnostic pipeline. In : Clayden P, Chon L, Collins S, Har‐
rington M, Jefferys R, Jimenez E, Morgan S, Swan T, Syed J, Wingfield C. (eds.)
Treatment Action Group. HIV, tuberculosis, and viral hepatitis drugs, diagnosis,
vaccines, immune-based therapies, and preventive technologies in development.
Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand
http://dx.doi.org/10.5772/54852
259
London : TAG; 2010. p107-124. http://www.treatmentactiongroup.org (accessed 31
August 2012).
[30] Mishra B, Rockey SM, Gupta S, Srinivasa H, Muralidharan S. Multidrug-resistant
tuberculosis : the experience of an urban tertiary care hospital in South India using
automated BACTEC 460 TB. Trop Doct 2012; 42 (1) : 35-37.
[31] Deun A Van, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis :
reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14 (2) : 131-140.
[32] Bemer P, Palicova F, Ru฀sch-Gerdes S, Drugeon HB, Pfyffer GE. Multicenter evaluation
of fully automated BACTEC mycobacteria growth indicator tube 960 system for
susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40 (1) :
150-154.
[33] Dang TM, Nguyen TN, Wolbers M, Vo SK, Hoang TT, Nguyen HD, et al. Evaluation of
microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant
tuberculosis in Vietnam. BMC Infect Dis 2012 Mar 1; 12 : 49.
[34] Guillerm M, Usdin M, Arkinstall J., editors. Tuberculosis diagnosis and drug sensitivity
testing, an overview of the current diagnostic pipeline. Geneva : Me′decins Sans Frontie
′res : Campaign for Access to Essential Medicines; 2006. http://www.access@gene‐
va.msf.org and http://www.accessmed-msf.org (accessed 11 September 2012).
[35] Bonnet M, Gagnidze L, Varaine F, Ramsay A, Githui W, Guerin PJ. Evaluation of
FASTPlaqueTBTM to diagnose smear-negative tuberculosis in a peripheral clinic in
Kenya. Int J Tuberc Lung Dis 2009; 13 (9) : 1112-1118.
[36] Piuri M, Jacobs WR Jr, Hatfull GF. Fluoromycobacteriophages for rapid, specific, and
sensitive antibiotic susceptibility testing of Mycobacterium tuberculosis. PLoS ONE 2009;
4(3): e4870. DOI: 10.1371/journal.pone.0004870
[37] Rondo′n L, Piuri M, Jacobs WR Jr, Waard Jde, Hatfull GF, Takiff HE. Evaluation of
fluoromycobacteriophages for detecting drug resistance in Mycobacterium tuberculosis.
J Clin Microbiol 2011; 49 (5) : 1838-1842.
[38] Musa HR, Ambroggi M, Souto A, A฀ngeby KAK. Drug susceptibility testing of
Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-
positive sputum samples. J Clin Microbiol 2005; 43 (7) : 3159-3161.
[39] Martin A, Paasch F, Von Groll A, Fissette K, Almeida P, Varaine F, et al. Thin-layer agar
for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium
tuberculosis isolates. Int J Tuberc Lung Dis 2009; 13 (10) : 1301-1304.
[40] Minion J, Leung E, Menzies, Pai M. Microscopic-observation drug susceptibility and
thin layer agar assays for the detection of drug resistant tuberculosis : a systematic
review and meta-analysis. Lancet Infect Dis 2010; 10 (10) : 688-698.
Tuberculosis - Current Issues in Diagnosis and Management260
[41] Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid
detection of multidrug resistance in Mycobacterium tuberculosis : a systematic review
and meta-analysis. J Antimicrob Chemother 2007; 59 (2) : 175-183.
[42] Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribo′n W, et al. Multicenter
laboratory validation of the colorimetric-redox indicator (CRI) assay for the rapid
detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. J Antimicrob
Chemother 2011; 66 (4) : 827-833.
[43] Rossau R, Traore H, Beenhouwer Hde, Mijs W, Jannes G, Rijk Pde, et al. Evaluation of
the INNO-LiPA Rif.TB assay, a reverse hybridization assay for the simultaneous
detection of Mycobacterium tuberculosis complex and its resistance to rifampicin.
Antimicrob Agents Chemother 1997; 41 (10) : 2093-2098.
[44] Viveiros M, Leandro C, Rodrigues L, Almeida J, Bettencourt R, Couto I, et al. Direct
application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of
Mycobacterium tuberculosis complex strains and detection of rifampicin resistance in 360
smear-positive respiratory specimens from an area of high incidence of multidrug-
resistant tuberculosis. J Clin Microbiol 2005; 43 (9) : 4880-4884.
[45] Abebe G, Paasch F, Apers L, Rigouts L, Colebunders R. Tuberculosis-drug resistance
testing by molecular methods : opportunities and challenges in resource-limited
settings. J Microbiol Methods 2011; 84 (2) : 155-160.
[46] O′Grady J, Bates M, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, et al. Evaluation of
the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tubercu‐
losis and HIV infection are highly endemic. Clin Infect Dis 2012 Aug 23. [Epub ahead
of print].
[47] Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, et al. Rapid and
accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert
MTB/RIF assay-a clinical validation study. PLoS ONE 2011; 6 (6) : e20458. DOI : 10.1371/
journal.pone.0020458
[48] Shimizu Y, Dobashi K, Yoshikawa Y, Yabe S, Higuchi S, Koike Y, et al. Five-antituber‐
culosis drug-resistance genes detection using array system. J Clin Biochem Nutr 2008;
42 (3) : 228-234.
[49] Wilson ML. Recent advances in the laboratory detection of Mycobacterium tuberculosis
complex and drug resistance. Clin Infect Dis 2011; 52 (11) : 1350-1355.
[50] Cha J, Lee HY, Lee KS, Koh WJ, Kwon OJ, Yi CA, et al. Radiological findings of
extensively drug-resistant pulmonary tuberculosis in non-AIDS adults : comparisons
with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol
2009; 10 (3) : 207-216.
[51] Lee ES, Park CM, Goo JM, Yim JJ, Kim HR, Lee IS, et al. Computed tomography features
of extensively drug-resistant pulmonary tuberculosis in non-HIV-infected patients. J
Comput Assist Tomogr 2010; 34 (4) : 559-563.
Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand
http://dx.doi.org/10.5772/54852
261
[52] Sneag DB, Schaaf HS, Cotton MF, Zar HJ. Failure of chemoprophylaxis with standard
antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.
Pediatr Infect Dis J 2007; 26 (12) : 1142-1146.
[53] Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug-
resistant pulmonary tuberculosis treatment regimens and patient outcomes : an
individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9 (8) : e1001300.
DOI : 10.1371/journal.pmed.1001300
[54] Falzon D, Jaramillo E, Schünemenn HJ, Arentz M, Bauer M, Bayona J , et al. WHO
guidelines for the programmatic management of drug-resistant tuberculosis. Eur
Respir J 2011; 38 (3) : 516-528.
[55] Nathanson E, Weezenbeek L-van, Rich ML, Gupta R, Bayona J, Blöndal K, et al.
Multidrug-resistant tuberculosis management in resource-limited settings. Emerg
Infect Dis 2006; 12 (9) : 1389-1397.
[56] Cheepsattayakorn A, Cheepsattayakorn R. The outcome of tuberculosis control in
special high-risk populations in northern Thailand : an observational study. Journal of
Health Systems Research 2009; 3 (4) : 558-566.
[57] Joseph P, Desai VBR, Fredrick JS, Ramachandran R, Raman B, Wares F, et al. Outcome
of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian
J Med Res 2011; 133 (5) : 529-534.
[58] Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, et al.
Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-
Natal, South Africa. Int J Tuberc Lung Dis 2010; 14 (4) : 420-426.
[59] Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, et al.
Predictors of sputum culture conversion among patients treated for multidrug-
resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16 (10) : 1335-1343.
[60] Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment
outcomes and HIV status of patients with extensively drug-resistant tuberculosis in
South Africa : a retrospective cohort study. Lancet 2010; 375 (9728) : 1798-1807.
[61] Well CD. Global impact of multidrug-resistant pulmonary tuberculosis among HIV-
infected and other immunocompromised hosts : epidemiology, diagnosis, and strat‐
egies for management. Curr Infect Dis Rep 2010; 12 (3) : 192-197.
[62] Shenoi SV, Brooks RP, Barbour R, Altice F, Zelterman D, Moll AP, et al. Survival from
XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS
ONE 2012;7(3):e31786. DOI : 10.1371/journal.pone.0031786
[63] LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22 (2) :
167-173.
[64] Monedero I, Caminero JA. MDR-/XDR-TB management : what it was, current stand‐
ards and what is ahead. Expert Rev Respir Med 2009; 3 (2) : 133-145.
Tuberculosis - Current Issues in Diagnosis and Management262
[65] Monedero I, Caminero JA. Management of multidrug-resistant tuberculosis : an
update. Ther Adv Respir Dis 2010; 4 (2) : 117-127.
[66] Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children : a
survival guide for paediatricians. Paediatr Respir Rev 2011; 12 (1) : 31-38.
[67] Mellado Peña MJ, Baquero-Artigao F, Moreno-Perez D; Grupo de Trabajo de Tuber‐
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